Brief Introduction
Dr. Hsin-Chen Lin is an attending physician in the Division of Medical Oncology at Taichung Veterans General Hospital, Taiwan. His clinical interests include UGI tract malignancy, especially pancreatic, gastric, and biliary tract cancers, and neuroendocrine tumor, with a focus on systemic therapy and multidisciplinary care. He is actively involved in clinical research in gastrointestinal oncology.
Specialty
GI tract malignancy (gastric cancer, pancreatic cancer, cholangiocarcinoma), neuroendocrine tumor, soft tissue sarcoma.
Education
- M.D. (2004 - 2011): China Medical University
Experience
- 2018 - 2024: Attending Physician, Division of Hematology/Oncology, Department of Medicine, Taichung Veterans General Hospital
- 2024 - Present: Attending Physician, Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital
Selected Publications
- Tseng KY, Chen YJ, Hsu CY, Shih YH, Lin HC. The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study. BMC Cancer. 2025 Jul 22;25(1):1200.
- Tsai YC, Lin HC, Hsu CY, Wu FH, Luo SC, Shih YH. Lymph Node Ratio as a Risk Factor for Early Recurrence in Older Patients with Stage II/III Gastric Cancer: A Retrospective Study. J Clin Med. 2025 Sep 19;14(18):6609.
- Lin HC, Tseng KY, Shih YH. Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network. Ther Adv Med Oncol. 2025 Nov 7:17:17588359251393064.
- Tseng KY, Hsu CY, Shih YH, Lin HC. Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. Therapeutic Advances in Medical Oncology. 2026;18.